CA2503669A1 - New anti-asthmatic drug (asmakure) from indigenous herbs to cure the disease asthma - Google Patents
New anti-asthmatic drug (asmakure) from indigenous herbs to cure the disease asthma Download PDFInfo
- Publication number
- CA2503669A1 CA2503669A1 CA002503669A CA2503669A CA2503669A1 CA 2503669 A1 CA2503669 A1 CA 2503669A1 CA 002503669 A CA002503669 A CA 002503669A CA 2503669 A CA2503669 A CA 2503669A CA 2503669 A1 CA2503669 A1 CA 2503669A1
- Authority
- CA
- Canada
- Prior art keywords
- formulation
- unique
- herb
- asmakure
- asthma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000006673 asthma Diseases 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 229940079593 drug Drugs 0.000 title claims abstract description 16
- 230000001088 anti-asthma Effects 0.000 title claims abstract description 8
- 239000000924 antiasthmatic agent Substances 0.000 title claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 10
- 235000008216 herbs Nutrition 0.000 title claims description 8
- 201000010099 disease Diseases 0.000 title claims description 6
- 206010011224 Cough Diseases 0.000 claims abstract description 5
- 240000004836 Justicia adhatoda Species 0.000 claims abstract description 4
- 239000003172 expectorant agent Substances 0.000 claims abstract description 4
- 230000003419 expectorant effect Effects 0.000 claims abstract description 4
- 210000003630 histaminocyte Anatomy 0.000 claims abstract description 4
- 208000037976 chronic inflammation Diseases 0.000 claims abstract description 3
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims abstract description 3
- 206010061218 Inflammation Diseases 0.000 claims abstract 4
- 230000002757 inflammatory effect Effects 0.000 claims abstract 4
- 230000004054 inflammatory process Effects 0.000 claims abstract 4
- 206010006451 bronchitis Diseases 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 7
- 229930013930 alkaloid Natural products 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 3
- 231100000086 high toxicity Toxicity 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 230000000813 microbial effect Effects 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 239000000341 volatile oil Substances 0.000 claims description 3
- 230000003435 bronchoconstrictive effect Effects 0.000 claims description 2
- 229940124630 bronchodilator Drugs 0.000 claims description 2
- 231100000957 no side effect Toxicity 0.000 claims description 2
- 206010003645 Atopy Diseases 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 239000000314 lubricant Substances 0.000 claims 3
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 claims 3
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 claims 3
- 229940075559 piperine Drugs 0.000 claims 3
- 235000019100 piperine Nutrition 0.000 claims 3
- 208000009079 Bronchial Spasm Diseases 0.000 claims 2
- 206010006482 Bronchospasm Diseases 0.000 claims 2
- 241000196324 Embryophyta Species 0.000 claims 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 2
- YIICVSCAKJMMDJ-SNVBAGLBSA-N Peganine Chemical compound C1=CC=C2N=C3[C@H](O)CCN3CC2=C1 YIICVSCAKJMMDJ-SNVBAGLBSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000000844 anti-bacterial effect Effects 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 2
- 239000012674 herbal formulation Substances 0.000 claims 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims 2
- 150000003180 prostaglandins Chemical class 0.000 claims 2
- 241000697341 Abies spectabilis Species 0.000 claims 1
- 208000014181 Bronchial disease Diseases 0.000 claims 1
- 241000605072 Cinnamomum verum Species 0.000 claims 1
- 235000004310 Cinnamomum zeylanicum Nutrition 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- YIICVSCAKJMMDJ-UHFFFAOYSA-N L-vasicine Natural products C1=CC=C2N=C3C(O)CCN3CC2=C1 YIICVSCAKJMMDJ-UHFFFAOYSA-N 0.000 claims 1
- SDIVYZXRQHWCKF-UHFFFAOYSA-N L-vasicinone Natural products C1=CC=C2C(=O)N3CCC(O)C3=NC2=C1 SDIVYZXRQHWCKF-UHFFFAOYSA-N 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- YIICVSCAKJMMDJ-JTQLQIEISA-N Peganine Natural products C1=CC=C2N=C3[C@@H](O)CCN3CC2=C1 YIICVSCAKJMMDJ-JTQLQIEISA-N 0.000 claims 1
- 241000722363 Piper Species 0.000 claims 1
- 244000203593 Piper nigrum Species 0.000 claims 1
- 235000008184 Piper nigrum Nutrition 0.000 claims 1
- WEFMOGRHGUPGMA-SNVBAGLBSA-N Vasicinol Natural products OC1=CC=C2N=C3[C@H](O)CCN3CC2=C1 WEFMOGRHGUPGMA-SNVBAGLBSA-N 0.000 claims 1
- WEFMOGRHGUPGMA-JTQLQIEISA-N Vasicinol Chemical compound OC1=CC=C2N=C3[C@@H](O)CCN3CC2=C1 WEFMOGRHGUPGMA-JTQLQIEISA-N 0.000 claims 1
- SDIVYZXRQHWCKF-SECBINFHSA-N Vasicinone Natural products C1=CC=C2C(=O)N3CC[C@@H](O)C3=NC2=C1 SDIVYZXRQHWCKF-SECBINFHSA-N 0.000 claims 1
- SDIVYZXRQHWCKF-VIFPVBQESA-N Vasicinone Chemical compound C1=CC=C2C(=O)N3CC[C@H](O)C3=NC2=C1 SDIVYZXRQHWCKF-VIFPVBQESA-N 0.000 claims 1
- 244000273928 Zingiber officinale Species 0.000 claims 1
- 235000006886 Zingiber officinale Nutrition 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000007883 bronchodilation Effects 0.000 claims 1
- 230000000994 depressogenic effect Effects 0.000 claims 1
- 208000017574 dry cough Diseases 0.000 claims 1
- 238000007908 dry granulation Methods 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 235000008397 ginger Nutrition 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 229960001340 histamine Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000002085 irritant Substances 0.000 claims 1
- 231100000021 irritant Toxicity 0.000 claims 1
- YAORRSXETYGIGC-UHFFFAOYSA-N isovasicinone Natural products C1=CC=C2C(=O)N3C(O)CCC3=NC2=C1 YAORRSXETYGIGC-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000004531 microgranule Substances 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 229930001457 monocyclic sesquiterpene Natural products 0.000 claims 1
- 150000001374 monocyclic sesquiterpene derivatives Chemical class 0.000 claims 1
- 230000000510 mucolytic effect Effects 0.000 claims 1
- 239000005445 natural material Substances 0.000 claims 1
- 229930014626 natural product Natural products 0.000 claims 1
- 230000003389 potentiating effect Effects 0.000 claims 1
- 230000001624 sedative effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000001841 zingiber officinale Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 2
- 208000000059 Dyspnea Diseases 0.000 abstract 1
- 206010013975 Dyspnoeas Diseases 0.000 abstract 1
- 206010036790 Productive cough Diseases 0.000 abstract 1
- 208000005392 Spasm Diseases 0.000 abstract 1
- 206010047924 Wheezing Diseases 0.000 abstract 1
- 210000000621 bronchi Anatomy 0.000 abstract 1
- 210000003123 bronchiole Anatomy 0.000 abstract 1
- 230000004047 hyperresponsiveness Effects 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 201000009240 nasopharyngitis Diseases 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 abstract 1
- 208000013220 shortness of breath Diseases 0.000 abstract 1
- 208000024794 sputum Diseases 0.000 abstract 1
- 210000003802 sputum Anatomy 0.000 abstract 1
- 230000001515 vagal effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 6
- 238000011049 filling Methods 0.000 description 3
- 235000017807 phytochemicals Nutrition 0.000 description 3
- 229930000223 plant secondary metabolite Natural products 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000002372 labelling Methods 0.000 description 2
- 229940124225 Adrenoreceptor agonist Drugs 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 239000004044 bronchoconstricting agent Substances 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000002026 carminative effect Effects 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Asthma is defined as a chronic inflammatory disorder of the airways of the respiratory organ. It is characterized by reversible airflow obstruction causing cough, wheeze, chest lightness and shortness of breath. The inflammation of bronchial wall together with increased eosinophilis and othe r inflammatory products of the mast cells and lymphocytes further induce the hyper responsiveness of the bronchi so that it in turn, narrows more rapidly in response to a wide range of stimuli. Asmakure the anti-asthma drug has properties with proven pharmacological use for alleviating common cold and persistent cough and finally building up of immunity against recurrence of Asthma. One of the ingredients Adhatoda Vasica Nees (Basak) has a definite expectorant action. In acute bronchitis, it is found to afford immediate relief especially when the sputum is thick and tenacious. The depression of the Vagal terminals further relieves irritation and spasm of the bronchioles .
Description
NEW ANTI-ASTHMATIC DRUG (ASMAKURE) FROM INDIGENOUS HERBS
TO CURE THE DISEASE ASTHMA
FIELD OF INVENTION
The conventional treatment of asthma is mostly focused on managing the disease rather than finding a permanent solution to the problem . Asmakure is distinctive in its formulation as it covers all mediators acting as broncho-constrictors while other prevalent herbal medicines largely aim at only single mediator called leukotrienes. Asmakure , thus goes to the root of asthmatic disorder and eliminates it in a unique manner. Further,with regular use of Asmakure, patients who are on oral steroid therapy, inhaled steroids and bronchodilators or in extreme cases on inhaled adrenoreceptor agonists etc. , would gradually find themselves weaned away from the use thereof. All these unique features of Asmakure constitute its field of invention as a unique medicine.
BACKGROUND OF INVENTION WITH REGARD TO THE DRAWBACK OF ASSOCIATED WITH
KNOWN ART
Asthma is an inflammatory disorder of respiratory system with breathing difficulties. There are some drugs available in the modern medicines (steroid, 13 adrenoreceptor agonist, mast cell stabilizer, brochodilator) to treat asthma. All the modern drugs have restriction of their treatment due to their high toxicity. And none of them are curative medicines for treating asthma. After a prolonged period of extensive research, our group of scientists have ultimately invented one unique anti asthmatic drug which has no side effect. Clinically it has been revealed that this new invention has positive curative value in asthma treatment.
DESCRIPTION OF THE INVENTION
Modern drugs have limited curative effect in the treatment of asthma as they hardly offer a permanent relief from the dreaded disease. Having seen the helplessness of the suffering humanity, we have finally come out with our research based anti-asthmatic drug, which is 100%
natural and aims at complete control and elimination of the disease.
As asthma is defined as a chronic inflammatory disorder of the airways, we have now invented a herbal based drug with ingredients which have known properties for expectorant action and promoting expulsion of bronchial secretions. Further aided by ingredients having carminative and astringent properties, Asmakure has ability to offer complete curative treatment for people suffering not only from Asthma but also builds up complete and full immunity against comman cough and cold.
DETAILED DESCRIPTION OF THE INVENTION WITH REFERENCES TO THE DRAWING
Procurement of raw materials Raw materials were procured from authentic sources. Phytochemical tests for checking the raw materials: Chemical tests for carbohydrates , tannins , alkaloids , anthraquinones , fixed oils and fats , volatile oils and resins , were performed. Morphological and anatomical studies were carried out with the different parts of the material. For powdered drugs, microscopical examinations were done. Thus through the phytochemical tests , quality of the herb materials was authenticated.
Process for leaf extract preparation of Adhatoda Vasica Fresh leaves of the plant Adhatoda Vasica were collected in the month of Oct-nov. The leaves were washed with double distilled water (with preservative to check any microbial contamination) and dried leaves were grinded in a pulverizer and passed through the mesh #
100. The grinded leaves powder were then extracted in a soxhlet extractor with water and alcohol at pH 6.5. The extracted materials were then dried in a spray drier.
The specification of the leaf extract is as follows:
1. Loss on drying 3.36% - 4.15 2. 60% Al. Soluble Extractives 89.62% -95%
TO CURE THE DISEASE ASTHMA
FIELD OF INVENTION
The conventional treatment of asthma is mostly focused on managing the disease rather than finding a permanent solution to the problem . Asmakure is distinctive in its formulation as it covers all mediators acting as broncho-constrictors while other prevalent herbal medicines largely aim at only single mediator called leukotrienes. Asmakure , thus goes to the root of asthmatic disorder and eliminates it in a unique manner. Further,with regular use of Asmakure, patients who are on oral steroid therapy, inhaled steroids and bronchodilators or in extreme cases on inhaled adrenoreceptor agonists etc. , would gradually find themselves weaned away from the use thereof. All these unique features of Asmakure constitute its field of invention as a unique medicine.
BACKGROUND OF INVENTION WITH REGARD TO THE DRAWBACK OF ASSOCIATED WITH
KNOWN ART
Asthma is an inflammatory disorder of respiratory system with breathing difficulties. There are some drugs available in the modern medicines (steroid, 13 adrenoreceptor agonist, mast cell stabilizer, brochodilator) to treat asthma. All the modern drugs have restriction of their treatment due to their high toxicity. And none of them are curative medicines for treating asthma. After a prolonged period of extensive research, our group of scientists have ultimately invented one unique anti asthmatic drug which has no side effect. Clinically it has been revealed that this new invention has positive curative value in asthma treatment.
DESCRIPTION OF THE INVENTION
Modern drugs have limited curative effect in the treatment of asthma as they hardly offer a permanent relief from the dreaded disease. Having seen the helplessness of the suffering humanity, we have finally come out with our research based anti-asthmatic drug, which is 100%
natural and aims at complete control and elimination of the disease.
As asthma is defined as a chronic inflammatory disorder of the airways, we have now invented a herbal based drug with ingredients which have known properties for expectorant action and promoting expulsion of bronchial secretions. Further aided by ingredients having carminative and astringent properties, Asmakure has ability to offer complete curative treatment for people suffering not only from Asthma but also builds up complete and full immunity against comman cough and cold.
DETAILED DESCRIPTION OF THE INVENTION WITH REFERENCES TO THE DRAWING
Procurement of raw materials Raw materials were procured from authentic sources. Phytochemical tests for checking the raw materials: Chemical tests for carbohydrates , tannins , alkaloids , anthraquinones , fixed oils and fats , volatile oils and resins , were performed. Morphological and anatomical studies were carried out with the different parts of the material. For powdered drugs, microscopical examinations were done. Thus through the phytochemical tests , quality of the herb materials was authenticated.
Process for leaf extract preparation of Adhatoda Vasica Fresh leaves of the plant Adhatoda Vasica were collected in the month of Oct-nov. The leaves were washed with double distilled water (with preservative to check any microbial contamination) and dried leaves were grinded in a pulverizer and passed through the mesh #
100. The grinded leaves powder were then extracted in a soxhlet extractor with water and alcohol at pH 6.5. The extracted materials were then dried in a spray drier.
The specification of the leaf extract is as follows:
1. Loss on drying 3.36% - 4.15 2. 60% Al. Soluble Extractives 89.62% -95%
3. Heavy Metals Complies 4. Arsenic Complies 5. Microbial Count Complies Total Alkaloids (By HPLC Method) ~ _sn°i Mixing:
The sieved nine powdered herb materials (e.g. talishpatra, ada, golmorich, Bara-elaichi, dachini, Pipul , nisadal, etc.) were separately weighed and mixed thoroughly in a Double Cone Mixture (National Engg. Make) for 15 minutes (20-24 rotation/min). Properly mixed material was then collected in a closed container to avoid catching of moisture from the environment. Bulk density of the material was calculated (0.451 gm/cc) following the standard methods.
The room temperature was maintained at 24~ 1° C before filling.
The Powder filling in bottles The powdered mixture was then filled into bottles by semi-automatic powder filling machine.
Bottle sealing and labeling The filled bottles were transferred to a bottle sealing machine. After sealing , they were transferred to an automatic Capping machine and labeling machine.
QC Testing : The sample was taken at random from the sealed bottles for QC
testing like phytochemical test, pharmaceuticakl test (water content,etc).
The sieved nine powdered herb materials (e.g. talishpatra, ada, golmorich, Bara-elaichi, dachini, Pipul , nisadal, etc.) were separately weighed and mixed thoroughly in a Double Cone Mixture (National Engg. Make) for 15 minutes (20-24 rotation/min). Properly mixed material was then collected in a closed container to avoid catching of moisture from the environment. Bulk density of the material was calculated (0.451 gm/cc) following the standard methods.
The room temperature was maintained at 24~ 1° C before filling.
The Powder filling in bottles The powdered mixture was then filled into bottles by semi-automatic powder filling machine.
Bottle sealing and labeling The filled bottles were transferred to a bottle sealing machine. After sealing , they were transferred to an automatic Capping machine and labeling machine.
QC Testing : The sample was taken at random from the sealed bottles for QC
testing like phytochemical test, pharmaceuticakl test (water content,etc).
Claims (8)
The formulation unique as claimed in claim 1 wherein as many as nine (9) different authentic herbs (medicinal plants and other natural products) in the dry condition have been mixed thoroughly to form dry-dry powder form to get maximum efficacy.
The formulation as unique as claimed in claims 1-2 wherein the mesh size (#) of the powder is uniformly kept below 20.
The formulation as unique as claimed in claims 1-3 wherein the solubility of the powder is kept above 75% w/v in water.
The formulation as unique as claimed in claims 1-4 wherein the bulk density of the powder is kept around 0.750 gm/cc.
The formulation as unique as claimed in claims 1-5 wherein the strict manufacturing process also ensures that the dry powder form remains below 4% (v/w) and its microbial count within limit.
The formulation as unique as claimed in claims 1-6 wherein the formulation contains the extract of A. Vasica with alkaloids concentration not less than 1.5% (total alkaloids).
Asmakure the research, based product, thus, has high efficacy in the treatment of asthma with no side -effect making it a unique formulation offering permanent relief to such patients.
We claim to have invented a new anti asthmatic drug(ASMAKURE) from indigenous herbs to cure diseases asthma.
CLAIM NO.1:
A polyherbal formulation invented is designed to mitigate "Atopic Chronic Inflammatory Airways Disorders (ACIAD)" causing asthmatic attack based on the following claims which also include a unique processing technology.
CLAIM NO.2:
Water extract of A. Vasica is forced through a high r.p.m nozzle to get fine uniform droplets. The droplets are dried by hot laminar air flow. The materials are dried and passed through 60 - 80 mesh screens to get uniform micro granules. After dry granulation, the natural lubricant is added as fine powder and it is desirable for each micro granule to be covered with the lubricant. The lubricant tends to make surface of micro granules less susceptible to adhesion. This unique process called "Single Compartment Micro-granulation Technology (SCMT)" ensures unification of water extract of a herb with several selective dry herbs.
CLAIM NO.3:
1) Abies webbiana is high altitude herb found in the most difficult terrains of the Himalayas with a very high anti-ACIAD property, i.e. "anti-Atopic Chronic Inflammatory Airways Disorders"
2) Adhatoda vasica is herb to combat bronchial disorders. The principals of plant are alkaloids vasicine (mw 188,C11H12H20), vasicinone and vasicinol. The alkaloids are used as bronchodialators
3) Zingiber officinale is a herb containing essential oil like zingiberine and alphaterpinone. These essential oils have potent antibacterial properties which reduce the acuteness of bronchial infection.
4) Piper longhum is another kind of traditional herb whose active ingredient, monocyclic sesquiterpenes has counter irritant and analgesic properties for reducing muscular pain and inflammation. Thus, found in research most effective in bronchial spasm and inflammation.
5) Piper nigrum is a medicinal herb containing piperine which enhances bio-availability of other herbs used in the formulation.
6) Cinnamomum zeylanicum is the herb having depressant action on central nervous system (CNS) and thus, reduces stress induced asthma.
7) Ammomum subulatum is the herb which provides soothing effect on broncho pharangial region and has a broncho sedative action.
8) Nishadal is a kind of white crystalline natural substance which has mucolitic (i.e. liquifying effect on dry cough) and expectorant (i.e. expels liquefied cough) properties.
CLAIM NO.4:
Asmakure's "Multi-Dimensional Clinical Approach (MDCA)" is based on the unified action of the eight (8) indigenously found herbs as mentioned in claim 3 because:
It ensures mucolytic and expectorant functions leading to bronchodilation on one hand and on the other hand the poly herb preparation acts a complete mast cell stabilizer inhibiting release of broncho constricting chemicals like histamine, cytokines, prostaglandins (PGD2) etc. This "Multi-Dimensional Clinical Approach (MDCA)" of this poly herb preparation has not been matched by other existing formulations in the peer group.[IJPC, Vol3(No.7), December 2002.
CLAIM NO.5:
The poly-herb preparation apart from containing Vasicine alkaloid has herbs with active ingredients like monocyclic sesuiterpenes, Zingiberine piperine ensuring anti-bacterial action, reduction of bronchial spasm and inflammation. The presence of piperine has enhanced the bio availability of the formulation.
CLAIM NO.6:
The formula is unique as claimed in Claims 1-5 because the polyherbal preparation ASMAKUR is first of its kind in permanently curing "Atopic Chronic Inflammatory Airways Disorders (ACIAD)" where other medicines have restrictive application due to their high toxicity.
CLAIM NO.4:
Asmakure's "Multi-Dimensional Clinical Approach (MDCA)" is based on the unified action of the eight (8) indigenously found herbs as mentioned in claim 3 because:
It ensures mucolytic and expectorant functions leading to bronchodilation on one hand and on the other hand the poly herb preparation acts a complete mast cell stabilizer inhibiting release of broncho constricting chemicals like histamine, cytokines, prostaglandins (PGD2) etc. This "Multi-Dimensional Clinical Approach (MDCA)" of this poly herb preparation has not been matched by other existing formulations in the peer group.[IJPC, Vol3(No.7), December 2002.
CLAIM NO.5:
The poly-herb preparation apart from containing Vasicine alkaloid has herbs with active ingredients like monocyclic sesuiterpenes, Zingiberine piperine ensuring anti-bacterial action, reduction of bronchial spasm and inflammation. The presence of piperine has enhanced the bio availability of the formulation.
CLAIM NO.6:
The formula is unique as claimed in Claims 1-5 because the polyherbal preparation ASMAKUR is first of its kind in permanently curing "Atopic Chronic Inflammatory Airways Disorders (ACIAD)" where other medicines have restrictive application due to their high toxicity.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IN2001/000203 WO2003043627A1 (en) | 2001-11-19 | 2001-11-19 | New anti-asthmatic drug (asmakure) from indigenous herbs to cure the disease asthma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2503669A1 true CA2503669A1 (en) | 2003-05-30 |
Family
ID=11076410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002503669A Abandoned CA2503669A1 (en) | 2001-11-19 | 2001-11-19 | New anti-asthmatic drug (asmakure) from indigenous herbs to cure the disease asthma |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2002214251A1 (en) |
| CA (1) | CA2503669A1 (en) |
| WO (1) | WO2003043627A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107095993A (en) * | 2017-06-19 | 2017-08-29 | 马绪梅 | A kind of Chinese medicine for treating Respiratory Medicine bronchopulmonary aspergillosis |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2436063A (en) * | 2006-03-16 | 2007-09-19 | Nicholas John Larkins | Pharmaceutical composition for the treatment of excess mucous production |
| CN104474506A (en) * | 2014-11-29 | 2015-04-01 | 黄根强 | Traditional Chinese medicine composition for treating cough variant asthma |
| CN105012817B (en) * | 2015-08-05 | 2019-03-01 | 陈瑜 | A kind of cough-relieving is relievingd asthma and the Chinese medicine composition of eliminating the phlegm and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN191020B (en) * | 2000-03-28 | 2003-09-13 | Dabur Res Foundation |
-
2001
- 2001-11-19 CA CA002503669A patent/CA2503669A1/en not_active Abandoned
- 2001-11-19 AU AU2002214251A patent/AU2002214251A1/en not_active Abandoned
- 2001-11-19 WO PCT/IN2001/000203 patent/WO2003043627A1/en not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107095993A (en) * | 2017-06-19 | 2017-08-29 | 马绪梅 | A kind of Chinese medicine for treating Respiratory Medicine bronchopulmonary aspergillosis |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003043627A1 (en) | 2003-05-30 |
| AU2002214251A1 (en) | 2003-06-10 |
| AU2002214251A8 (en) | 2003-06-10 |
| WO2003043627A8 (en) | 2006-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7422760B2 (en) | Plant-based medicament for the treatment of Hepatitis C | |
| Musthaba et al. | Patented herbal formulations and their therapeutic applications | |
| CN117379484B (en) | Cattle and sheep pneumonia aerosol and preparation method and application thereof | |
| Borquaye et al. | Anti-inflammatory, antioxidant and total phenolic content of the ethanolic extracts of Celtis africana Burm. f | |
| CA2503669A1 (en) | New anti-asthmatic drug (asmakure) from indigenous herbs to cure the disease asthma | |
| CN103520031A (en) | Plant formula used as natural preservative | |
| Uwaya et al. | ESTIMATIONS OF PHYTOCHEMICAL COMPOSITION AND NON-ENZYMATIC ANTIOXIDANT, AND ANTITUSSIVE, EXPECTORANT AND ANALGESIC PROPERTIES OF POLYHERBAL-FORMULATED TEA | |
| CN106620541B (en) | A kind of external medicine composition for treating chronic eczema and preparation method thereof | |
| Kushwaha et al. | Standardization of some ayurvedic formulation used in Covid-19 | |
| CN115969898A (en) | A snus buccal tablet for preventing and treating oral ulcer and its preparation method | |
| CN103446564B (en) | Chinese medicine composition of a kind of anti-inflammation and preparation method thereof | |
| CN107050177A (en) | It is a kind of to be used to treat Chinese medicine composition of acne and preparation method thereof | |
| CN107320531B (en) | A kind of traditional Chinese medicine active component for external treatment of common cold and its production method | |
| Gupta et al. | Review on phytochemicals and pharmacological activities of Boerhaavia diffusa Linn. | |
| CN112089767A (en) | Compound traditional Chinese medicine bacteriostatic agent, preparation method and application thereof | |
| Sani et al. | Clinical evaluation of Boerhaavia diffusa L. extract obtained from different geographical sources | |
| Siriwatanametanon et al. | Investigation of antimicrobial activity of 13 Thai medicinal plants against bacteria and fungi | |
| CN115887243B (en) | A kind of hydrogel beauty liquid and preparation method thereof | |
| Sagar et al. | Therapeutic Study of Garlic Gel Formulation for Tongue Ulcer Healing | |
| CN119925481B (en) | Pummelo peel powder for respiratory tract health and preparation method and application thereof | |
| Sagar et al. | Formulation and Evaluation of Garlic Gel for Tongue Ulcer | |
| CN108295023A (en) | A kind of Chinese medicinal toothpaste and preparation method thereof | |
| Priya et al. | ANTIOXIDANT AND ANTI INFLAMMATORY PROPERTIES OF FLEMINGIA WIGHTIANA ETHANOLIC EXTRACT | |
| CN115154571A (en) | A kind of antibacterial composition and its application | |
| Tiwari et al. | DIURETIC ACTIVITY OF ASHWAGA DHARISHTA PREPARED BY TRADITIO AL AD MODER METHODS I EXPERIME TAL RATS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |